Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack

Biotechnology Journal

Volumn 9, Issue 9, 2014, Pages 1104-1114

  Henderson, David ^a   Ogilvie, Lesley A ^b,c   Hoyle, Nicholas ^d   Keilholz, Ulrich ^e   Lange, Bodo ^c   Lehrach, Hans ^b,c,f  

^a BAYER PHARMA AG   (Germany)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^c ALACRIS THERANOSTICS GMBH   (Germany)

^d ROCHE DIAGNOSTICS GMBH   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f Dahlem Centre for Genome Research and Medical Systems Biology   (Germany)

Author keywords

Biomarkers; Colon cancer; Next generation sequencing; Personalized medicine; Tumor heterogeneity

Indexed keywords

BIOLOGY; BIOMARKERS; DIAGNOSIS; TUMORS;

CLINICAL APPLICATION; COLON CANCER; FUNCTIONAL ANNOTATION; INNOVATIVE MEDICINES; NEXT-GENERATION SEQUENCING; PERSONALIZED MEDICINES; TECHNOLOGICAL ADVANCES; TUMOR HETEROGENEITY;

DISEASES;

ANTINEOPLASTIC AGENT; TUMOR MARKER;

COLONIC NEOPLASMS; GENETICS; GENOMICS; HUMAN; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; SYSTEMS BIOLOGY;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; COLONIC NEOPLASMS; GENOMICS; HUMANS; PRECISION MEDICINE; SYSTEMS BIOLOGY;

EID: 84906946254     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201400109     Document Type: Review

References (91)

1. O'Keefe, S. J. D., Nutrition and colonic health: The critical role of the microbiota. Curr. Opin. Gastroenterol. 2008, 24, 51-58.
2. Hanahan, D., Weinberg, R. A., The hallmarks of cancer. Cell 2000, 100, 57-70.
3. Hanahan, D., Weinberg, R. A., Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
4. Luengo-Fernandez, R., Leal, J., Gray, A., Sullivan, R., Economic burden of cancer across the European Union: A population-based cost analysis. Lancet Oncol. 2013, 14, 1165-1174.
5. Spear, B. B., Heath-Chiozzi, M., Huff, J., Clinical application of pharmacogenetics. Trends Mol. Med. 2001, 7, 201-204.
6. Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W. et al., The sequence of the human genome. Science 2001, 291, 1304-1351.
7. Collins, F. S., Lander, E. S., Rogers, J., Waterston, R. H., Conso, I. H. G. S., Finishing the euchromatic sequence of the human genome. Nature 2004, 431, 931-945.
8. Dulbecco, R., A turning point in cancer-research - sequencing the human genome. Science 1986, 231, 1055-1056.
9. Leary, R. J., Lin, J. C., Cummins, J., Boca, S. et al., Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc. Natl. Acad. Sci. USA 2008, 105, 16224-16229.
10. Parsons, D. W., Jones, S., Zhang, X., Lin, J. C. et al., An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321, 1807-1812.
11. Parmigiani, G., Boca, S., Lin, J., Kinzler, K. W. et al., Design and analysis issues in genome-wide somatic mutation studies of cancer. Genomics 2009, 93, 17-21.
12. Meyerson, M., Gabriel, S., Getz, G., Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 2010, 11, 685-696.
13. Schweiger, M. R., Hussong, M., Rohr, C., Lehrach, H., Genomics and epigenomics of colorectal cancer. Wiley Interdiscip. Rev. Syst. Biol. 2013, 5, 205-219.
14. Schweiger, M. R., Kerick, M., Timmermann, B., Isau, M., The power of NGS technologies to delineate the genome organization in cancer: From mutations to structural variations and epigenetic alterations. Cancer Metastasis. Rev. 2011, 30, 199-210.
15. Wood, L. D., Parsons, D. W., Jones, S., Lin, J. et al., The genomic landscapes of human breast and colorectal cancers. Science 2007, 318, 1108-1113.
16. Koboldt, D. C., Fulton, R. S., McLellan, M. D., Schmidt, H. et al., Comprehensive molecular portraits of human breast tumours. Nature 2012, 490, 61-70.
17. Muzny, D. M., Bainbridge, M. N., Chang, K., Dinh, H. H. et al., Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487, 330-337.
18. Pleasance, E. D., Cheetham, R. K., Stephens, P. J., McBride, D. J. et al., A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463, 191-196.
19. Pleasance, E. D., Stephens, P. J., O'Meara, S., McBride, D. J. et al., A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010, 463, 184-190.
20. Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L. et al., Patterns of somatic mutation in human cancer genomes. Nature 2007, 446, 153-158.
21. Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R. et al., Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455, 1069-1075.
22. Watson, I. R., Takahashi, K., Futreal, P. A., Chin, L., Emerging patterns of somatic mutations in cancer. Nat. Rev. Genet. 2013, 14, 703-718.
23. Sjoblom, T., Jones, S., Wood, L. D., Parsons, D. W. et al., The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314, 268-274.
24. Irizarry, R. A., Ladd-Acosta, C., Wen, B., Wu, Z. J. et al., The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 2009, 41, 178-186.
25. Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S. et al., Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17, 510-522.
26. Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014, 505, 495-501.
27. Yang, D., Sun, Y., Hu, L. M., Zheng, H. et al., Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 2013, 23, 705-705.
28. Weinstein, J. N., Akbani, R., Broom, B. M., Wang, W., Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507, 315-322.
29. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R. et al., Signatures of mutational processes in human cancer. Nature 2013, 500, 415-421.
30. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J., Stratton, M. R., Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013, 3, 246-259.
31. Hudson, T. J., Anderson, W., Aretz, A., Barker, A. D. et al., International network of cancer genome projects. Nature 2010, 464, 993-998.
32. Jones, D. T. W., Jager, N., Kool, M., Zichner, T. et al., Dissecting the genomic complexity underlying medulloblastoma. Nature 2012, 488, 100-105.
33. Jones, D. T., Hutter, B., Jager, N., Korshunov, A. et al., Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat. Genet. 2013, 45, 927-932.
34. Weischenfeldt, J., Simon, R., Feuerbach, L., Schlangen, K. et al., Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013, 23, 159-170.
35. Deisboeck, T. S., Wang, Z. H., Macklin, P., Cristini, V., Multiscale cancer modeling. Annu. Rev. Biomed. Eng. 2011, 13, 127-155.
36. Edelman, L. B., Eddy, J. A., Price, N. D., In silico models of cancer. Wiley Interdiscip. Rev. Syst. Biol. 2010, 2, 438-459.
37. Enderling, H., Rejniak, K. A., Simulating cancer: Computational models in oncology. Front. Oncol. 2013, 3, 233.
38. Faratian, D., Bown, J. L., Smith, V. A., Langdon, S. P., Harrison, D. J., Cancer systems biology. Methods Mol. Biol. 2010, 662, 245-263.
39. Goryachev, A. B., Goryanin, I. I., Systems biology: Design principles of whole biological systems. Preface. Adv. Exp. Med. Biol. 2012, 736, v-vii.
40. Kreeger, P. K., Lauffenburger, D. A., Cancer systems biology: A network modeling perspective. Carcinogenesis 2010, 31, 2-8.
41. Chen, R., Snyder, M., Promise of personalized omics to precision medicine. Wiley Interdiscip. Rev. Syst. Biol. 2013, 5, 73-82.
42. Chen, R., Snyder, M., Systems biology: Personalized medicine for the future? Curr. Opin. Pharmacol. 2012, 12, 623-628.
43. Hood, L., Flores, M., A personal view on systems medicine and the emergence of proactive P4 medicine: Predictive, preventive, personalized and participatory. N. Biotechnol. 2012, 29, 613-624.
44. Trisilowati Mallet, D. G., In silico experimental modeling of cancer treatment. ISRN Oncol. 2012, 2012, 828701.
45. Cho, N. H., Kim, Y. B., Park, T. K., Kim, G. E. et al., P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. Gynecol. Oncol. 2003, 91, 346-353.
46. Oda, K., Matsuoka, Y., Funahashi, A., Kitano, H., A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 2005, 1, 20050010.
47. Purvis, J., Ilango, V., Radhakrishnan, R., Role of network branching in eliciting differential short-term signaling responses in the hypersensitive epidermal growth factor receptor mutants implicated in lung cancer. Biotechnol. Prog. 2008, 24, 540-553.
48. Shih, A. J., Purvis, J., Radhakrishnan, R., Molecular systems biology of ErbB1 signaling: Bridging the gap through multiscale modeling and high-performance computing. Mol. Biosyst. 2008, 4, 1151-1159.
49. Li, F., Thiele, I., Jamshidi, N., Palsson, B. O., Identification of potential pathway mediation targets in toll-like receptor signaling. PLoS Comput. Biol. 2009, 5, e1000292.
50. Vandin, F., Upfal, E., Raphael, B. J., De novo discovery of mutated driver pathways in cancer. Genome Res. 2012, 22, 375-385.
51. Bachmann, J., Raue, A., Schilling, M., Becker, V. et al., Predictive mathematical models of cancer signalling pathways. J. Intern. Med. 2012, 271, 155-165.
52. Vanneman, M., Dranoff, G., Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 2012, 12, 237-251.
53. Taneja, P., Maglic, D., Kai, F., Sugiyama, T. et al., Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development. Cancer Res. 2010, 70, 9084-9094.
54. Lievre, A., Bachet, J. B., Le Corre, D., Boige, V. et al., KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66, 3992-3995.
55. Wilson, P. M., LaBonte, M. J., Lenz, H. J., Molecular markers in the treatment of metastatic colorectal cancer. Cancer J. 2010, 16, 262-272.
56. Wilson, P. M., Lenz, H. J., Integrating biomarkers into clinical decision making for colorectal cancer. Clin. Colorectal Cancer 2010, 9, S16-S27.
57. Van Cutsem, E., Dicato, M., Arber, N., Berlin, J. et al., Molecular markers and biological targeted therapies in metastatic colorectal cancer: Expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann. Oncol: ESMO 2010, 21, vi1-10.
58. Seymour, M. T., Brown, S. R., Middleton, G., Maughan, T., Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial. Lancet Oncol. 2013, 14, 749-759.
59. Oliner, K. S., Douillard, J.-Y., Siena, S., Tabernero, J. et al., Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). J. Clin. Oncol. 2013, 31, abstr 3511.
60. Heinemann, V., Fischer von Weikersthal, L., Decker, T., Kiani, A. et al., Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). J. Clin. Oncol. 2013, 31, abstr LBA3506.
61. Meacham, C. E., Morrison, S. J., Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501, 328-337.
62. Labianca, R., Nordlinger, B., Beretta, G. D., Brouquet, A. et al., Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann. Oncol. 2010, 21, vi70-v77.
63. Pelizzola, M., Ecker, J. R., The DNA methylome. FEBS Lett. 2011, 585, 1994-2000.
64. Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S. et al., Cancer genome landscapes. Science 2013, 339, 1546-1558.
65. Burrell, R. A., McGranahan, N., Bartek, J., Swanton, C., The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013, 501, 338-345.
66. Junttila, M. R., de Sauvage, F. J., Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013, 501, 346-354.
67. Ma, Q., Lu, A.Y., Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol. Rev. 2011, 63, 437-459.
68. Valent, P., Bonnet, D., De Maria, R., Lapidot, T. et al., Cancer stem cell definitions and terminology: The devil is in the details. Nat. Rev. Cancer 2012, 12, 767-775.
69. Lui, Z., Fusi, A., Schmittel, A., Tinhofer, I. et al., Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine. Cancer Biol. Ther. 2010, 10, 860-864.
70. Alix-Panabières, C., Schwarzenbach, H., Pantel, K., Circulating tumor cells and circulating tumor DNA. Annu. Rev. Med. 2012, 63, 199-215.
71. Maheswaran, S., Sequist, L.V., Nagrath, S., Ulkus, L. et al., Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 2008, 359, 366-377.
72. Markiv, A., Rambaruth, N. D. S., Dwek, M. V., Beyond the genome and proteome: Targeting protein modifications in cancer. Curr. Opin. Pharmacol. 2012, 12, 408-413.
73. Bode, A. M., Dong, Z., Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 2004, 4, 793-805.
74. Hitosugi, T., Chen, J., Post-translational modifications and the Warburg effect. Oncogene 2013, DOI: 10.1038/onc.2013.406.
75. Spurrier, B., Ramalingam, S., Nishizuka, S., Reverse-phase protein lysate microarrays for cell signaling analysis. Nat. Protoc. 2008, 3, 1796-1808.
76. Soderberg, O., Gullberg, M., Jarvius, M., Ridderstrale, K. et al., Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods 2006, 3, 995-1000.
77. Fredriksson, S., Gullberg, M., Jarvius, J., Olsson, C. et al., Protein detection using proximity-dependent DNA ligation assays. Nat. Biotechnol. 2002, 20, 473-477.
78. Wegner, K. D., Lindén, S., Jin, Z., Jennings, T. L. et al., Nanobodies and nanocrystals: Highly sensitive quantum dot-based homogeneous FRET-immunoassay for serum-based EGFR detection. Small 2014, 10, 734-740 DOI. 10.1002/smll.20130238.
79. Geißler, D., Stufler, S., Löhmannsröben, H.-G., Hildebrandt, N., Six-color time-resolved Förster resonance energy transfer for ultrasensitive multiplexed biosensing. J. Am. Chem. Soc. 2013, 135, 1102-1109.
80. Geißler, D., Charbonnière, L. J., Ziessel, R. F., Butlin, N. G. et al., Quantum dot biosensors for ultra-sensitive multiplexed diagnostics. Angew. Chem. Int. Ed. 2010, 49, 1396-1401.
81. Morgner, F., Geißler, D., Stufler, S., Butlin, N. G. et al., A quantum-dot-based molecular ruler for multiplexed optical analysis. Angew. Chem. 2010, 49, 7570-7574.
82. Weibrecht, I., Lundin, E., Kiflemariam, S., Mignardi, M. et al., In situ detection of individual mRNA molecules and protein complexes or post-translational modifications using padlock probes combined with the in situ proximity ligation assay. Nat. Protoc. 2013, 8, 355-372.
83. Ke, R., Mignardi, M., Pacureanu, A., Svedlund, J. et al., In situ sequencing for RNA analysis in preserved tissue and cells. Nat. Methods 2013, 10, 857-860.
84. Klipp, E., Liebermeister, L., Wierling, C., Kowald, A. et al., Systems Biology. A Textbook, Wiley-Blackwell, Weinheim 2009, p. 592.
85. Wierling, C., Kuhn, A., Hache, H., Daskalaki, A. et al., Prediction in the face of uncertainty: A Monte Carlo-based approach for systems biology of cancer treatment. Mutat. Res. 2012, 746, 163-170.
86. Flicek, P., Ahmed, I., Amode, M. R., Barrell, D. et al., Ensembl 2013. Nucleic Acids Res. 2013, 41, D48-D55.
87. Kanehisa, M., Goto, S., Sato, Y., Kawashima, M. et al., Data, information, knowledge and principle: Back to metabolism in KEGG. Nucleic Acids Res. 2014, 42, D199-D205.
88. Hucka, M., Finney, A., Sauro, H. M., Bolouri, H. et al., The systems biology markup language (SBML): A medium for representation and exchange of biochemical network models. Bioinformatics 2003, 19, 524-531.
89. Li, C., Donizelli, M., Rodriguez, N., Dharuri, H. et al., BioModels database: An enhanced, curated and annotated resource for published quantitative kinetic models. BMC Syst. Biol. 2010, 4, 92.
90. Forbes, S., Clements, J., Dawson, E., Bamford, S. et al., Cosmic 2005. Br. J. Cancer 2006, 94, 318-322.
91. Rohr, C., Kerick, M., Fischer, A., Kuhn, A. et al., High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications. PLoS ONE 2013, 8, e67461.